Marta Hamilton

2.8k total citations
48 papers, 2.1k citations indexed

About

Marta Hamilton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Marta Hamilton has authored 48 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Marta Hamilton's work include Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Research Studies (12 papers). Marta Hamilton is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (13 papers) and Lung Cancer Research Studies (12 papers). Marta Hamilton collaborates with scholars based in United States, United Kingdom and Switzerland. Marta Hamilton's co-authors include Ashok Rakhit, Bert L. Lum, Julie Wolf, Karsten Witt, Michael Pantze, Steve Eppler, Jason Rusk, Gary M. Clark, Pablo J. Cagnoni and Jie Ling and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Marta Hamilton

47 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marta Hamilton United States	23	1.1k	791	657	312	182	48	2.1k
John F. Deeken United States	24	1.3k 1.3×	502 0.6×	948 1.4×	292 0.9×	266 1.5×	92	3.0k
Heather Shaw United States	20	1.8k 1.7×	821 1.0×	1.1k 1.6×	114 0.4×	412 2.3×	43	3.6k
Michael C. Cox United States	23	710 0.7×	746 0.9×	492 0.7×	239 0.8×	237 1.3×	53	2.7k
John M. Burke United States	27	1.2k 1.1×	472 0.6×	532 0.8×	672 2.2×	168 0.9×	177	3.1k
David L. Cutler United States	31	888 0.8×	544 0.7×	938 1.4×	627 2.0×	344 1.9×	145	3.9k
James D. Bearden United States	31	1.7k 1.6×	888 1.1×	304 0.5×	267 0.9×	265 1.5×	94	3.1k
E. Claire Dees United States	19	1.1k 1.0×	318 0.4×	575 0.9×	89 0.3×	318 1.7×	52	1.8k
Jean Jenkins United States	34	675 0.6×	198 0.3×	886 1.3×	132 0.4×	220 1.2×	97	3.8k
B. J. Kennedy United States	38	1.4k 1.3×	792 1.0×	784 1.2×	252 0.8×	535 2.9×	135	4.1k
Masaru Narabayashi Japan	28	1.0k 0.9×	881 1.1×	338 0.5×	129 0.4×	177 1.0×	96	2.6k

Countries citing papers authored by Marta Hamilton

Since Specialization

Citations

This map shows the geographic impact of Marta Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Hamilton more than expected).

Fields of papers citing papers by Marta Hamilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Hamilton. The network helps show where Marta Hamilton may publish in the future.

Co-authorship network of co-authors of Marta Hamilton

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Hamilton. A scholar is included among the top collaborators of Marta Hamilton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Hamilton. Marta Hamilton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manla, Yosef, et al.. (2025). A Case Series of Daratumumab Use in Pre-Heart Transplant Desensitization: Is It Always Effective?. The Journal of Heart and Lung Transplantation. 44(4). S638–S639.

Ailawadi, Gorav, Martin S. Polinsky, Dani Bitran, et al.. (2017). Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury. Kidney International Reports. 2(5). 836–843. 29 indexed citations

Hamilton, Marta, Julie Wolf, Daniel W. Drolet, et al.. (2014). The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemotherapy and Pharmacology. 73(3). 613–621. 41 indexed citations

Mita, Alain C., K. Papadopoulos, Maja J.A. de Jonge, et al.. (2011). Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British Journal of Cancer. 105(7). 938–944. 36 indexed citations

Ranson, Malcolm, Heather Shaw, Jürgen Wolf, et al.. (2009). A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemotherapy and Pharmacology. 66(1). 53–58. 30 indexed citations

Rakhit, Ashok, Michael Pantze, Scott Fettner, et al.. (2007). The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition. European Journal of Clinical Pharmacology. 64(1). 31–41. 108 indexed citations

Dragovich, Tomislav, Mark S. Huberman, Daniel D. Von Hoff, et al.. (2006). Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemotherapy and Pharmacology. 60(2). 295–303. 40 indexed citations

Frohna, Paul, Jianfeng Lu, Steve Eppler, et al.. (2006). Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects. The Journal of Clinical Pharmacology. 46(3). 282–290. 82 indexed citations

Ling, Jie, Kim A. Johnson, Zhuang Miao, et al.. (2005). METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS. Drug Metabolism and Disposition. 34(3). 420–426. 187 indexed citations

10.

Dark, G., A H Calvert, Robert Grimshaw, et al.. (2005). Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 23(9). 1859–1866. 33 indexed citations

11.

Gelmon, Karen A., Hal W. Hirte, B. Fisher, et al.. (2004). A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Investigational New Drugs. 22(3). 263–275. 22 indexed citations

12.

Desjardins, John, David L. Emerson, Blake Tomkinson, et al.. (2001). Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anti-Cancer Drugs. 12(3). 235–245. 15 indexed citations

13.

Loos, Walter J., Diederik F.S. Kehrer, Eric Brouwer, et al.. (2000). Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 738(1). 155–163. 19 indexed citations

14.

Emerson, David L., Raymond A. Bendele, Eric Brown, et al.. (2000). Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.. PubMed. 6(7). 2903–12. 51 indexed citations

15.

Hamilton, Marta, et al.. (1995). Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B Biomedical Sciences and Applications. 665(1). 171–181. 66 indexed citations

16.

Ehlhardt, William J., H. R. Sullivan, Paul G. Wood, et al.. (1993). Pharmacokinetics of the Anticancer Agent Sulofenur in Mice, Rats, Monkeys, and Dogs. Journal of Pharmaceutical Sciences. 82(7). 683–688. 5 indexed citations

17.

Hamilton, Marta, et al.. (1992). Sensitive method for the quantitation of nortriptyline and 10-hydroxynortriptyline in human plasma by capillary gas chromatography with electron-capture detection. Journal of Chromatography B Biomedical Sciences and Applications. 573(1). 141–145. 2 indexed citations

18.

Taylor, Charles W., David S. Alberts, W. Satterlee, et al.. (1989). Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.. Journal of Clinical Oncology. 7(11). 1733–1740. 38 indexed citations

19.

Hamilton, Marta, et al.. (1989). Placental transfer and fetal distribution of fluoxetine in the rat. Toxicology and Applied Pharmacology. 98(2). 198–205. 57 indexed citations

20.

Gunn, Julia K., et al.. (1989). Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor.. BMJ. 298(6678). 964.2–964. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact